CTRI/2010/091/001094已完成1 期
An open-label, randomized, single dose, two period,crossover study to determine the bioavailability ofvalsartan oral solution formulation relative to the valsartan tablet formulation (Diovan®) in healthy adult subjects
ovartis Healthcare Private Limited Andhra Pradesh India0 个研究点目标入组 30 人开始时间: 待定最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Ba/be
入排标准
入选标准
- •Healthy males and postmenopausal or surgically sterilized women of 18 to 45 years of age who grant informed consent
排除标准
- •Smokers, drug addicts, those having immunodeficiency diseases
研究者
相似试验
进行中（未招募）
1 期
Clinical trial in Healthy Volunteers to test Valsartan PharmacokineticsHypertensionEUCTR2016-004323-23-Outside-EU/EEAovartis86
已完成
不适用
Bioavailability study between Pirfenidone ER tablet 1200 mg and PIRFENEX (pirfenidone) 200 mg tablet in healthy human subjectsCTRI/2021/09/036729Cipla Ltd India60
尚未招募
不适用
Bioequialence study of two novel strengths of CoartemCTRI/2011/12/002256ovartis Healthcare Pvt Ltd120
进行中（未招募）
不适用
A research study to find out whether a product to be tested (salmeterol xinafoate HFA pMDI 25 µg per actuation, manufactured by Cipla Ltd, India) is equivalent to the already existing formulation (salmeterol xinafoate HFA pMDI 25 µg per actuation (Serevent Evohaler™), supplied by Allen and Hanburys, UK) when administered by a volumatic spacer device to children with asthmaMedDRA version: 17.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersAsthmaEUCTR2014-001946-10-BGCipla Ltd.80
已完成
不适用
Randomized, Open Label, Single-Dose, Two Period, Two Treatment, Two Sequence, Cross-over, Study to Compare the Pharmacokinetics, Pharmacodynamics and Safety of Rabeprazole Sodium Delayed-release Capsule 20 mg in Healthy Volunteers.CTRI/2017/07/008985Cadila Healthcare Limited12